Board of directors
Tom Schwarz is managing partner at the Life Sciences Fund Amsterdam (LSFA); an early stage venture capital fund that made the seed investment in AIMM Therapeutics in 2009. Schwarz joined AIMM as chairman of the board. With a venture capital track record that dates back to 1998, Schwarz has led a number of investment processes for companies including AIMM, ArgenX and Regenesance. Schwarz also co-founded the Erasmus MC Biomedical Fund and the Twente Technology Fund.